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 Abstract 23	
Adeno-associated virus (AAV) is a small human dependovirus whose low immunogenicity and 24	
capacity for long term persistence have led to its widespread use as vector for gene therapy. Despite 25	
great recent successes in AAV-based gene therapy, further improvements in vector technology may 26	
be hindered by an inadequate understanding of various aspects of basic AAV biology. AAV is unique 27	
in that its replication is largely dependent on a helper virus and cellular factors, and in the absence of 28	
coinfection, wild type AAV establishes latency through mechanisms that are not yet fully understood. 29	
Challenging the currently held model for AAV latency, we show here that the corepressor Krüppel-30	
associated box domain-associated protein 1 (KAP1) binds the latent AAV2 genome at the rep ORF, 31	
leading to trimethylation of AAV2-associated histone 3 lysine 9, and that the inactivation of KAP1 32	
repression is necessary for AAV2 reactivation and replication. We identify a new viral mechanism 33	
for the counteraction of KAP1, in which interference with the KAP1 phosphatase protein phosphatase 34	
1 (PP1) by the AAV2 Rep proteins mediates enhanced phosphorylation of KAP1-S824, and thus 35	
relief from KAP1 repression. Furthermore, we show that this phenomenon involves recruitment of 36	
the NIPP1 (nuclear inhibitor of PP1)-PP1α holoenzyme to KAP1 in a manner dependent upon the 37	
NIPP1 FHA domain, identifying NIPP1 as a novel interaction partner for KAP1 and shedding light 38	
on the mechanism through which PP1 regulates cellular KAP1 activity. 	39	
 40	
Significance statement 41	
In recent years, adeno-associated virus (AAV) has attracted considerable attention as a result of its 42	
success as a gene therapy vector. However, several aspects of its biology remain elusive. Given that 43	
AAV vectors mimic the latent phase of the viral life cycle, defining the mechanisms involved in the 44	
regulation of AAV latency is of particular importance. Our studies demonstrate, for the first time, 45	
that epigenetic processes are involved in the regulation of viral latency and reveal novel virus-host 46	
interactions and helper functions that are aimed at counteracting the epigenetic repression of the viral 47	
	 3	
genome during the lytic phase of the viral life cycle. These observations will inform the design of 48	
future AAV vector technologies. 49	
 50	
BODY 51	
 52	
Introduction 53	
Adeno-associated virus serotype 2 (AAV2) is a small, single-stranded DNA (ssDNA) parvovirus that 54	
has evolved a unique biphasic life cycle in which replication is dependent on both cellular host factors 55	
and coinfection by a helper virus such as adenovirus (Ad5) or herpesvirus (HSV-1) (1). Unable to 56	
replicate autonomously, infection by AAV2 alone leads to the establishment of latency either through 57	
long term episomal persistence (2), or through preferential integration of the viral genome into 58	
specific sites in the human genome (3–5). The current model for AAV2 latency states that the viral 59	
genome is silenced through simultaneous binding of the viral p5 promoter by the AAV2 master 60	
regulator Rep and the cellular transcription factors YY1 and MLTF, and that the induction of AAV2 61	
gene expression upon helper virus coinfection occurs through interactions between these factors and 62	
the helper factor Ad5 E1A or HSV-1 ICP0 (6–8). Despite the widely accepted view that latent AAV2 63	
is silenced exclusively through the binding of Rep and YY1 to p5, evidence that the viral genome 64	
assumes a chromatinized configuration shortly after infection (9, 10) suggests a role for epigenetic 65	
modification in the establishment of latency and/or transcriptional regulation. The epigenetic 66	
landscape of AAV remains unknown however.  67	
Recent years have seen a rapidly expanding interest in the AAV field as a result of its 68	
widespread use as a vector for gene therapy. Despite great recent successes in AAV-based gene 69	
therapy (11–16), further improvements may be hindered by an inadequate understanding of various 70	
aspects of basic AAV biology. Given that AAV vectors likely mimic the latent phase of the viral life 71	
cycle, defining the mechanisms involved in the regulation of AAV latency is of particular importance 72	
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for the future design and safety of improved vectors. In this study, we sought to gain insight into the 73	
regulation of AAV latency by using a screening approach known as BioID (17) to identify novel 74	
interaction partners for the AAV2 replication (Rep) proteins. BioID exploits the fusion of the 75	
promiscuous biotin ligase BirA* to a bait protein in order to trigger proximity-dependent 76	
biotinylation of neighboring proteins, thus allowing for the identification of a much broader scope of 77	
protein associations than achievable with conventional affinity purification.   78	
Screens were performed using each of the four related Rep isoforms – Rep78, Rep68, Rep52, 79	
and Rep40 – which together orchestrate every aspect of the viral life cycle. The large Rep proteins 80	
(Rep78/68) consist of an origin-binding domain (OBD) containing site-specific DNA binding and 81	
endonuclease activity (18) and an ATPase domain with helicase activity (19), and are necessary for 82	
viral replication, integration, and transcriptional regulation (20–22). The small Rep proteins 83	
(Rep52/40) share only the ATPase domain, and are involved mostly in viral packaging and 84	
transcriptional regulation (23, 24). In addition, Rep52 and Rep78 share a C-terminal zinc finger  85	
(ZNF) domain implicated in several protein interactions (25, 26). Our BioID screen identified the 86	
transcriptional corepressor Krüppel-associated box domain-associated protein 1 (KAP1/TRIM28/ 87	
TIF1-β) as an interaction partner of the Rep proteins and led to the discovery that Rep78 and Rep52 88	
interact with a protein complex containing KAP1, protein phosphatase 1 (PP1), and nuclear inhibitor 89	
of PP1 (NIPP1) in order to counteract KAP1-mediated repression of the latent viral genome. 90	
 91	
Results  92	
The latent AAV2 genome is repressed through KAP1 recruitment to the rep ORF and 93	
subsequent histone methylation. 94	
For the BioID screen, BirA* was fused to the N-terminus of each of the four Rep isoforms, and the 95	
BirA*-Rep fusion proteins were expressed in 293T cells in the presence of free biotin. Biotinylated 96	
proteins were affinity purified 48h after transfection and analyzed by LC-MS/MS. Identified in 97	
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lysates from each of the four screens was the corepressor KAP1, which acts to form transcriptionally 98	
repressive heterochromatin through the recruitment of chromatin-modifying proteins such as the 99	
histone methyltransferase SETDB1 and the NuRD histone deacetylase complex containing CHD3 100	
(27, 28).  Peptides identified for KAP1 are shown in Table S1. Several known interaction partners of 101	
the Rep proteins were also identified by BioID (Table S1), lending support to the quality and 102	
coherence of our results. The well documented function of KAP1 as a mediator of heterochromatin 103	
(29, 30)  combined with a growing body of evidence demonstrating a role for KAP1 in the regulation 104	
of viral elements (31–34) led us to focus our efforts on this candidate. With the exception of Rep68, 105	
the physical interaction between each of the Rep proteins and KAP1 was confirmed using 106	
biotinylation and immunoprecipitation assays (Fig. S1). Given that Rep40 represents the only shared 107	
domain between the Rep proteins, these results suggest that the central Rep ATPase domain is 108	
sufficient to mediate a Rep-KAP1 interaction but that the C-terminal ZNF domain of Rep78 is 109	
necessary to stabilize this interaction in the presence of an N-terminal OBD.  110	
To explore the possible significance of the Rep-KAP1 interaction in the AAV life cycle, we 111	
next performed viral replication experiments in cells depleted for KAP1. 293T cells were transduced 112	
with lentiviral vectors expressing either a shRNA targeting the 3’ UTR of KAP1 (shKAP1), or the 113	
corresponding empty vector (shEMPTY). 48h later, cells were infected with Ad5 alone, AAV2 alone, 114	
or coinfected with Ad5 and AAV2 in order to initiate productive replication.  Viral replication and 115	
transcription were analyzed approximately 42h after infection, or when cells displayed optimal 116	
cytopathic effect. AAV2 replication was undetectable in either KAP1-depleted or control cells in the 117	
absence of Ad5, however this was expected as AAV2 is known to be dependent on several helper 118	
factors to initiate replication. In the context of coinfection however, a 5-6-fold enhancement in AAV2 119	
genome replication, transcription, and protein expression was observed in KAP1-depleted cells as 120	
compared to controls (Fig. 1 A and B, Fig. S2), Importantly, complementation of KAP1-depleted 121	
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cells with exogenous KAP1 restored baseline levels of AAV2 replication and protein expression (Fig. 122	
1C, Fig. S2). 123	
We next asked if KAP1 could be repressing AAV2 through its recruitment to the viral genome 124	
and subsequent formation of heterochromatin. We performed KAP1-specific chromatin 125	
immunoprecipitation (ChIP) on 293T cells 2 days after infection with AAV2 alone and analyzed the 126	
purified chromatin by qPCR using primers specific for various regions of the AAV2 genome. 127	
GAPDH was used as a negative control, and two zinc finger genes, ZNF180 and ZNF274, as positive 128	
controls (35). KAP1 binding was detected across rep, particularly at the 5’ and middle regions (Fig. 129	
1D, Fig. S3), corresponding with the genomic location of the AAV2 p19 promoter. Binding was 130	
accordingly lost in KAP1-depleted cells, confirming the observed signal was KAP1-dependent. To 131	
determine the functional significance of this binding, we also performed ChIP-qPCR for H3K9me3, 132	
a known marker for KAP1-mediated repression. H3K9me3 was enriched across the AAV2 genome 133	
(Fig. 1E, Fig. S3), spreading downstream from KAP1 binding sites in rep. Furthermore, this 134	
enrichment appeared to be KAP1-dependent as H3K9 trimethylation was lost in KAP1-depleted cells 135	
at a ratio similar to what was observed for controls ZNF180 and ZNF274. Importantly, depletion of 136	
CHD3 and SETDB1, two members of the KAP1 repressive complex (27, 28), independently and 137	
cooperatively led to an enhancement in AAV2 replication and protein expression (Fig. 1 F, G, and 138	
H). Taken together, these data strongly suggest that KAP1 represses AAV2 through the binding of 139	
AAV2 rep and the subsequent recruitment of histone and chromatin modifying proteins, which then 140	
act together to methylate AAV2-associated H3K9.    141	
 142	
Inactivation of KAP1 repression through phosphorylation of serine 824 is necessary to support 143	
AAV2 transcriptional activation and lytic replication.  144	
Upon DNA damage, ATM-dependent phosphorylation of KAP1 at serine 824 (p-KAP1-S824) results 145	
in release of the repressive complex, relaxation of heterochromatin, and relief of transcriptional 146	
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repression (36, 37). We questioned whether AAV2 replication was associated with KAP1-S824 147	
phosphorylation, which would suggest a requirement for the inactivation of KAP1 corepressor 148	
activity. We first explored this possibility by monitoring levels of phosphorylated KAP1-S824 in 149	
cells infected with increasing concentrations of either AAV2 or recombinant AAV2 (rAAV2) in the 150	
presence of Ad5. rAAV2 is comprised of only the viral inverted terminal repeats (ITRs) flanking a 151	
GFP transgene cassette, and as such is replication defective. However, the ITRs are known to recruit 152	
components of the Mre11/Rad50/NBS1 (MRN) complex – the principal mediator of ATM activation 153	
– and could potentially trigger KAP1-S824 phosphorylation (38). We therefore used rAAV2 to 154	
control for the input of these structures.  155	
A clear dose-dependent increase in KAP1-S824 phosphorylation was observed in 293T cells 156	
coinfected with Ad5 and increasing concentrations of AAV2 (Fig. 2A). This was not observed in 157	
the presence of rAAV2, which is replication defective and therefore additionally requires Rep and 158	
Cap in trans for replication (Fig. 2A), suggesting that active AAV2 replication is necessary to trigger 159	
KAP1-S824 phosphorylation and not simply the viral structure represented by rAAV2. In addition, 160	
H3K9me3-specific ChIP performed in cells coinfected with AAV2 and Ad5 revealed a complete 161	
loss of H3K9 trimethylation on lytic AAV2 genomes, indicating that release of the KAP1 repressive 162	
complex is necessary to support lytic replication (Fig. 2B). The observation that AAV2 replication 163	
levels are reduced in cells overexpressing wild-type KAP1 (KAP1WT) (Fig. 2C) and enhanced with 164	
overexpression of the dominant negative phospho-mimetic KAP1-S824D mutant (KAP1S824D) (Fig. 165	
2D) further supports a functional role for KAP1-S824 phosphorylation in AAV2 replication. 166	
Furthermore, KAP1-depleted cells complemented with KAP1S824D supported enhanced levels of 167	
AAV2 replication and protein expression, which were comparable to those observed in KAP1-168	
depleted cells, whereas complementation with the phospho-ablatant mutant KAP1S824A restored 169	
replication and protein expression to baseline levels (Fig. 2 E and F).  170	
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To determine whether KAP1-S824 phosphorylation constitutes a viral reactivation switch, we 171	
looked at the effect of KAP1-S824 phosphorylation on basal expression levels from the three AAV 172	
promoters in the absence of helper virus coinfection. AAV transcription during latency is virtually 173	
undetectable, and furthermore it has been well established that a helper factor such as Ad5 E1A is 174	
essential for activation of the p5 promoter (6). To observe measurable effects on basal AAV2 175	
transcription, these experiments were therefore necessarily performed in 293T cells, which are 176	
transformed with AdV E1/E2 and can thus support extremely low levels of AAV transcription 177	
without helper virus coinfection. Cells depleted for KAP1 and reconstituted with KAP1WT, 178	
KAP1S824D, or KAP1S824A were infected with AAV2 alone and harvested 14h post-infection for 179	
transcriptional analysis. Both KAP1-depleted cells and cells reconstituted with KAP1S824D supported 180	
2- to 6-fold greater levels of basal transcription from the three AAV2 promoters, while 181	
complementation with KAP1WT and KAP1S824A restored transcription to negligible levels (Fig. 2G).  182	
  183	
Rep52 and Rep78 mediate phosphorylation of KAP1-S824 through interactions with the 184	
protein phosphatase PP1.  185	
We next performed a time course of lytic replication to determine if phosphorylation of KAP1-186	
S824 could be related to the onset of Rep expression. Substantially elevated levels of p-KAP1-187	
S824 were apparent 18h after infection with Ad5 and AAV2, correlating well with the onset of Rep 188	
expression and leading us to ask if the Rep proteins might be directly modulating KAP1 activity 189	
(Fig. 3A). To address this, cells expressing various mutants of the Rep proteins were monitored for 190	
p-KAP1-S824 levels. The large Rep proteins possess endonuclease activity shown to trigger DNA 191	
damage (25, 39), and all four Rep proteins share a helicase domain with the potential to also disrupt 192	
DNA. In order to minimize the possibility of DDR-dependent induction of p-KAP1-S824 via ATM, 193	
endonuclease mutants (Y156F) of Rep68 and Rep78, and catalytic ATPase mutants (K340H) of all 194	
four Rep proteins were used (40, 41).  Substantially elevated levels of p-KAP1-S824 were apparent 195	
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in the presence of both Rep52 and Rep78, independently from either endonuclease or ATPase 196	
activity (Fig. 3B). Basal levels of p-KAP1-S824 were also visible with Rep40 and Rep68 but were 197	
3- to 6-fold lower than for Rep52 and Rep78. These data suggest that the Rep proteins, in particular 198	
Rep52 and Rep78, actively mediate phosphorylation of KAP1-S824 via an unknown pathway, 199	
independently from their ability to cause DNA damage. This idea was further supported by 200	
transfection and infection experiments performed in the presence of an ATM inhibitor (ATMi), 201	
which demonstrated that ATM activation is not necessary for the observed Rep-mediated 202	
phosphorylation of KAP1-S824 (Fig. S4). Given that Rep52 and Rep78 share a C-terminal ZNF 203	
domain not present in Rep40 or Rep68, we suspected this region might also be important for the 204	
phosphorylation of KAP1-S824. Expression of a series of C-terminal truncation mutants, in which 205	
the Rep52/Rep78 ZNF domain was progressively removed (Fig. S5), completely abrogated 206	
phosphorylation of KAP1-S824 while having no effect on the Rep-KAP1 interaction (Fig. S5), 207	
suggesting that the Rep proteins act through an intermediary protein(s).  208	
Potential cellular factors that could be interacting with Rep to control the phosphorylation 209	
state of KAP1-S824 include protein phosphatase 1 (PP1) and its specific regulators. Upon 210	
completion of DNA repair, basal levels of p-KAP1-S824 are restored through the combined 211	
activities of PP1α/β and protein phosphatase 4 (42, 43).  Several regulatory subunits of PP1 were 212	
identified as interaction partners for Rep alongside KAP1 in our original BioID screen, leading us 213	
to hypothesize that the Rep proteins could be interfering with this pathway and antagonizing PP1 214	
activity. Co-IP experiments in cells expressing Rep52 and GFP-tagged PP1-α, -β, or -γ indicated a 215	
physical interaction between Rep52, PP1α, and PP1γ (Fig. 3C). Furthermore, AAV2 lytic 216	
replication and transcription were enhanced with depletion of PP1α but not PP1β (Fig. 3 D, E, and 217	
F), supporting observations from the co-IP as well as a role for PP1 antagonism in the AAV life 218	
cycle. Interestingly, this effect was most pronounced at early time points indicating that PP1 might 219	
act predominantly during early infection events, such as transcriptional activation.  220	
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Using the conserved PP1 consensus binding sequence [KR][X0-1][VI]{P}[FW] (44) as our 221	
guideline, we identified one putative non-canonical binding site in the Rep ATPase domain 222	
(372KMVIW376), partially overlapping with the Walker B motif (Fig. S6). Co-IP experiments 223	
using FLAG-tagged PP1α confirmed a physical interaction between Rep52 and PP1α (Fig. 3G). 224	
Mutation of the first lysine in the putative binding site (K372A) did not affect this interaction 225	
however (Fig. 3G), indicating this region may not represent a true PP1 binding site. Alternatively, 226	
it is possible that this region acts together with the Rep ZNF domain to bind PP1. Interestingly 227	
however, the K372A mutation completely abrogated Rep-mediated phosphorylation of KAP1-228	
S824 (Fig. 3H) without affecting the ability of Rep to regulate the AAV2 p5 promoter (45) or 229	
interact with KAP1 (Fig. S6). There is precedence to indicate that a functional interaction between 230	
PP1 and its regulatory subunits is based on multiple points of interaction, only one of which 231	
necessarily consists of the conserved binding site. Furthermore it has been demonstrated that 232	
mutation of only one interaction site may be sufficient to abolish the regulation of PP1 while being 233	
insufficient to abolish the physical association between PP1 and its regulatory component (46, 47). 234	
It is therefore possible that the mutation of additional yet unidentified interaction sites in Rep would 235	
be necessary to disrupt Rep-PP1 binding, while mutation of only the PP1 binding site is sufficient 236	
to abolish regulation of PP1 by Rep.  237	
 238	
The Rep proteins interfere with the formation of a KAP1-NIPP1-PP1 complex to inhibit KAP1-239	
S824 dephosphorylation by PP1. 240	
The free PP1 catalytic subunit has exceptionally broad substrate specificity. PP1 activity is 241	
therefore regulated through its interactions with numerous PP1-interacting-proteins (PIPs), which 242	
can inhibit PP1 or act as substrate specifiers (48). To further define a potential mechanism for the 243	
above observations, we next looked at the nuclear inhibitor of PP1 (NIPP1/PPP1R8), a major 244	
regulator of PP1 that was identified alongside KAP1 in our BioID screen. NIPP1 contains three 245	
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functional domains: (1) an N-terminal Forkhead Associated (FHA) protein interaction domain, (2) a 246	
central PP1-binding domain containing the consensus PP1-binding motif, and (3) a multifunctional 247	
C-terminal domain that binds RNA, has endoribonuclease activity, and inhibits PP1 activity via an 248	
unknown mechanism (46, 49, 50). Cross-linked GFP-trap experiments in cells expressing Rep52 with 249	
various NIPP1 mutants (Fig. 4A) fused to eGFP revealed that KAP1 and Rep are recruited to NIPP1 250	
via the N-terminal FHA domain, forming a complex with the NIPP1-PP1α holoenzyme (Fig. 4B). 251	
PP1α has previously been shown to form a constitutive unit with KAP1 at certain promoters (42). 252	
Our results suggest however that, in this instance, the interaction between KAP1 and PP1 is mediated 253	
through NIPP1. Recruitment was dependent upon the NIPP1 FHA domain, which binds 254	
hyperphosphorylated proteins through a dipeptide motif consisting of phospho-threonines followed 255	
by a proline. Although no function has yet been attributed to it, one such motif exists at threonine 256	
541 of KAP1 suggesting that it may be directly recruited to NIPP1 via the FHA domain.  Levels of 257	
p-KAP1-S824 were elevated in cells overexpressing NIPP1-WT compared to cells expressing the 258	
PP1-binding mutant NIPP1-RATA, supporting a role for the inhibition of PP1 by NIPP1 in KAP1 259	
phosphorylation (Fig. 4 C and D). Surprisingly, p-KAP1-S824 levels were also elevated in the 260	
presence of NIPP1-FHAm. It is possible that the residual binding observed between KAP1 and 261	
NIPP1-FHAm (Fig. 4B) is sufficient to support the regulation of phosphorylation. Alternatively, 262	
overexpression of NIPP1-FHAm may act to constitutively inhibit the nuclear pool of PP1. In addition, 263	
NIPP1-WT and NIPP1-FHAm, but not NIPP1-RATA, enhanced Rep-mediated phosphorylation of 264	
KAP1-S824 (Fig. 4 E and F), supporting the idea that this pathway is exploited by Rep to maintain 265	
enhanced levels of p-KAP1-S824 during infection.  266	
To further explore the role for Rep in this pathway, we performed cross-linked GFP-trap 267	
experiments in cells expressing NIPP1-WT-eGFP with either wild type Rep52, or the 268	
phosphorylation-deficient Rep52-K372A (Fig. 4G). Interestingly, recruitment of KAP1 to NIPP1 269	
appeared to be independent of Rep52 entirely, while abundance of PP1α in the complex was 270	
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significantly decreased in the presence of Rep52, but not Rep52-K372A. The loss of PP1α was 271	
associated with increased p-KAP1-S824 and a concomitant loss of SETDB1, supporting the 272	
hypothesis that Rep52 mediates phosphorylation of KAP1-S824 through PP1 interference in order to 273	
counteract KAP1 repression.  Furthermore, as loss of PP1α from the complex was observed with 274	
Rep52 but not Rep52-K372A, these results suggest that the K372A mutation may in fact interfere 275	
with the Rep-PP1 interaction in the context of endogenous PP1 even though we did not observe an 276	
effect with overexpressed FLAG-PP1α (Fig. 3G). 277	
 278	
Targeting of KAP1 as a novel helper function for AAV2 replication. 279	
Given that basal levels of Rep expression during latency are not sufficient to counteract KAP1 and 280	
that depletion of KAP1 alone is not sufficient to trigger AAV2 transcription and replication, we 281	
hypothesized that AAV2 helper viruses might act as a biological switch necessary to allow for the 282	
upregulation of rep expression prior to the onset of KAP1 phosphorylation. KAP1 protein levels were 283	
significantly depleted in 293T and HeLa cells infected with increasing concentrations of Ad5 and 284	
were restored in the presence of 5µM of the proteasome inhibitor MG132 (Fig.  S7). Interestingly, 285	
Ad5 E1B55K has been shown to interfere with KAP1 SUMOylation during early infection (51), 286	
presenting the possibility that hypoSUMOylated KAP1 may be targeted by the cell for proteosomal 287	
degradation. Similar results were also observed for HSV-1, another AAV helper virus (Fig.  S7), 288	
suggesting that KAP1 targeting may represent an unknown helper function for AAV2 replication 289	
necessary to release the viral genome from its latent state. 290	
 291	
Discussion 292	
Significant breakthroughs in AAV vector design have previously been derived from an 293	
enhanced understanding of basic AAV biology. There are still many aspects of the AAV life cycle 294	
that remain elusive however. Of particular relevance to AAV vectors, whose biology may mimic that 295	
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of latent viral genomes, the nature and contribution of epigenetic marks to the genome organization 296	
and temporal gene regulation of wild type AAV is not yet known. In the present study, we employed 297	
a BioID strategy to screen for novel interaction partners of the AAV2 Rep proteins in an effort to 298	
elucidate the mechanisms involved in the establishment of and release from AAV2 latency. This 299	
approach led to the discovery that the transcriptional corepressor KAP1 interacts with three of the 300	
four Rep proteins and is recruited to the latent AAV2 genome, where it mediates transcriptional 301	
repression through the formation of heterochromatin.  302	
Our findings bear interesting parallels with observations made for the regulation of both 303	
KSHV and CMV latency by KAP1. Recruitment of KAP1 to the CMV genome leads to H3K9me3 304	
deposition across various lytic genes, while latency-associated genes remain free from repressive 305	
marks (32). Similarly, latency associated nuclear antigen (LANA)-mediated recruitment of KAP1 to 306	
the KSHV genome is essential for the shutdown of lytic gene expression during early stages of 307	
infection (52). Here, we observed KAP1-dependent deposition of H3K9me3 across the latent AAV2 308	
genome, spreading downstream from KAP1 recruitment sites near the p19 promoter in rep in a 309	
manner consistent with the mechanism of long-range heterochromatin spreading shown to establish 310	
KAP1-mediated repression of KRAB-ZFP clusters (53). Interestingly, no enrichment for KAP1 or 311	
H3K9me3 was detected at the p5 promoter, a region whose transactivating activity is necessary for 312	
initiation from all three viral promoters. It will be interesting to determine whether this region is 313	
protected from repressive marks in order to ensure rapid and dynamic regulation of p5 upon 314	
reactivation.  315	
In agreement with a role for KAP1 as a repressor of latent AAV2, both KAP1 depletion and 316	
expression of a repression-deficient phosphomimetic KAP1-S824D mutant resulted in enhanced lytic 317	
replication, transcription, and protein expression in cells coinfected with AAV2 and Ad5. This effect 318	
was not observed in cells infected with AAV2 alone however, reflecting the dependency of AAV2 319	
on various helper factors to initiate replication and suggesting that KAP1 repression provides a 320	
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second layer of regulation, the antagonism of which is necessary but not sufficient for reactivation. 321	
Similar observations were made for both KSHV and CMV. KSHV replication was enhanced, but not 322	
triggered, by KAP1 depletion, both in the context of induced KRta expression and hypoxia-induced 323	
KSHV reactivation (31, 54). Similarly, TNFα-mediated NF-κB induction was necessary for the full 324	
reactivation of CMV upon KAP1 depletion (32). It is well established that reactivation of AAV2 is 325	
dependent upon interactions between helper factors such as Ad5 E1A and cellular factors YY1 and 326	
MLTF bound to the p5 promoter region. Our observation that levels of basal AAV2 transcription in 327	
latently infected 293T cells were enhanced in cells either depleted for KAP1 or reconstituted with 328	
KAP1-S824D however strongly indicates that KAP1 binding additionally serves to silence the viral 329	
genome through histone methylation, even while the p5 promoter may be minimally activated by low 330	
levels of E1A. We therefore propose that AAV2 reactivation is dependent upon the removal of 331	
repressive H3K9me3 from the viral genome in order to render it transcriptionally competent and 332	
allow for E1A-mediated activation of p5, and thus, transactivation of all three viral promoters.  333	
It is also interesting to note that KSHV, CMV, and AAV2 are episomal viruses with the ability 334	
to modulate KAP1 activity, which are clearly capable of replication without the need for KAP1 335	
depletion, suggesting the intriguing possibility that these viruses have domesticated KAP1 repression 336	
to their advantage. It is possible for example that heterochromatinization allows latent episomes to 337	
better evade immune recognition, or that it may prevent deleterious recombination events and/or 338	
genome degradation. Upon reactivation, KSHV directly mediates phosphorylation of KAP1 via its 339	
viral kinase vPk (31), and, although it is has not yet been established which CMV protein is 340	
responsible, phosphorylation of KAP1-S824 was only ever observed in cells that were also positive 341	
for CMV IE antigens (32). Here, we show that AAV2 Rep52 and Rep78 mediate the inactivation of 342	
KAP1 repression by inhibiting its dephosphorylation by the phosphatase PP1α. Rep expression 343	
reduced the abundance of PP1α from a complex comprised of KAP1, SETDB1, PP1α, and NIPP1, 344	
and this was dependent upon the presence of an intact putative PP1-binding site in Rep, suggesting 345	
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that Rep52 achieves enhanced phosphorylation of KAP1-S824 by sequestering PP1 from the 346	
complex.  347	
Although we have shown that Rep can mediate the phosphorylation of KAP1 independently 348	
from ATM activation, this does not exclude a role for the activation of effectors of the DDR in the 349	
context of a productive infection. In fact, the nature of the mechanism outlined above presupposes 350	
an initial trigger for KAP1 phosphorylation, and both helper virus and productive AAV2 infections 351	
are known to trigger robust activation of DDR proteins (55, 56). Taken together, these data suggest 352	
a two-part mechanism in which helper factors or the DDR upon viral infection trigger the initial 353	
phosphorylation of KAP1, a signal then potentiated through Rep-mediated antagonism of PP1 during 354	
lytic replication. We envision that the inactive NIPP1-PP1 holoenzyme forms a constitutive 355	
regulatory unit with KAP1, effectively serving to tether inactive PP1 to KAP1 for rapid regulation 356	
(Fig. S8). NIPP1 does not systematically inhibit PP1 activity however. Rather, inhibition is dependent 357	
upon interactions between PP1 bound to the central domain of NIPP1 and the inhibitory C-terminal 358	
domain of NIPP1, which additionally has RNA binding and endoribonuclease activity (46, 47). This 359	
interaction can be interrupted through the simultaneous phosphorylation of tyrosine 335 in the C-360	
terminal domain and binding of RNA, effectively activating the PP1-NIPP1 holoenzyme (46).	Upon 361	
initiation of a DDR, when KAP1 is rapidly phosphorylated, NIPP1 inhibition of PP1 may be 362	
inactivated through RNA-binding and phosphorylation of the C-terminal region of NIPP1 by the 363	
DDR-responsive tyrosine kinase Lyn (46), allowing PP1 to rapidly restore basal levels of p-KAP1-364	
S824. The role of the Rep proteins might then be to sequester PP1, or compete for binding, in order 365	
to sustain high levels of p-KAP1-S824 and support lytic infection (Fig. 5, Fig. S8). 	366	
This work demonstrates not only the first example of PP1 targeting by a parvovirus, but also 367	
the first example of PP1 targeting for the purpose of regulating KAP1 activity. It will be interesting 368	
to determine whether this mechanism might extend to other members of the parvovirus family, or if 369	
known viral targets of KAP1 such as KSHV and CMV might also manipulate this pathway to achieve 370	
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relief from KAP1 repression. PP1 has previously been shown to form a constitutive unit with KAP1 371	
at the p21 promoter, where it is thought to set a basal transcription rate as well as to rapidly restore 372	
KAP1 corepressor function after ATM activation by regulating KAP1-S824 phosphorylation (42). 373	
There is no evidence for free cellular pools of PP1 however. Rather, PP1 constitutes the catalytic unit 374	
of a large array of multisubunit holoenzymes, which regulate and target PP1 activity to prevent 375	
uncontrolled protein dephosphorylation and cell death (48). It has yet to be determined what PP1 376	
interacting protein (PIP) is responsible for regulating PP1 activity towards KAP1. Our finding that 377	
KAP1, PP1, and NIPP1 exist as a complex sheds light on this question and suggests that PP1 may be 378	
targeted to KAP1 via the NIPP1 FHA domain where it is then dynamically regulated by NIPP1 to 379	
maintain homeostatic levels of phosphorylated KAP1-S824.  380	
This work further presents the first evidence that AAV2 latency is regulated in part 381	
through the epigenetic modification of its genome, challenging the long-standing model for AAV 382	
latency whereby the viral genome is silenced exclusively through binding of the p5 promoter by 383	
cellular factors YY1 and MLTF, and the Rep proteins (6, 57). The findings presented here have 384	
additional relevance for gene therapy, as our data highlight the possibility that current production 385	
helper plasmids may lack helper genes that may be critical for navigating host responses. 386	
Understanding the epigenetic control of AAV may also shed light on the intriguing and unexplained 387	
resistance of AAV gene therapy vectors to host shut off, and will undoubtedly contribute to 388	
understanding the consequences of integrating wild type and recombinant viruses. In addition, the 389	
recent controversial discovery of AAV2 sequences in human liver tumors (58) has caused some to 390	
call into question the safety of rAAV vectors and has highlighted the need to further explore AAV2 391	
regulation of latency. These findings may thus provide key insights into the impact and contribution 392	
of AAV2 latency on the development of human diseases. 393	
 394	
 395	
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Methods 396	
Cell lines and viruses 397	
293T human embryonic kidney cells and HeLa human cervical epithelial cells were obtained from 398	
the American Tissue Culture Collection (ATCC). Cells were cultured in Dulbecco’s modified Eagle’s 399	
(DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Invitrogen) plus 1% 400	
Pen/Strep (Sigma) and were tested for mycoplasma once per month. 401	
AAV2 and human adenovirus type 5 (Ad5) were produced and purified as previously described (59). 402	
 403	
BioID Screening  404	
Ten 10cm dishes of 293T cells per BirA*-Rep construct were transfected using 6µg DNA and 50µl 405	
PEI in 500µl serum-free (SF) medium per dish. 6h post-transfection, the medium was replaced with 406	
fresh DMEM + 10% FBS, and D-Biotin (Life Technologies) was added to a final concentration of 407	
100µM. 48h post-transfection, cells were harvested for LC-MS/MS analysis as previously described 408	
(17). Mass spectrometry was performed by the KCL Proteomics Facility at Denmark Hill. 409	
 410	
Immunoprecipitation 411	
 293T cells were transfected in a 6-well format with 200ng of Rep-expressing constructs, and 250ng 412	
of FLAG-PP1α or FAG-GFP using 8µl PEI in 80µl serum free (SF) medium. 48h after transfection, 413	
cells were lysed in RIPA buffer, and lysates were incubated with 2µg anti-FLAG (Sigma, F7425) for 414	
1.5h on a rotator at 4°C. 40µl of protein G agarose beads (Pierce) were added and incubated a further 415	
3h. Beads were washed 4 times in RIPA buffer, and proteins were eluted from beads by boiling at 416	
95oC for 10 minutes in 60µl 2X Laemmli buffer.  417	
 418	
Cross-linking Immunoprecipitation 419	
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  293T cells were transfected in a 6-well format with 200ng of Rep-expressing constructs, and 750ng 420	
of FLAG-GFP, FLAG-KAP1, or GFP-NIPP1 using 8µl PEI in 80µl SF medium. 48 hours after 421	
transfection cells were fixed in 350µl 0.05% formaldehyde for 10 minutes at 37°C and then quenched 422	
in 350µl 0.125M glycine, pH 7, for 5 minutes at room temperature before being lysed in 500µl cross-423	
linking IP buffer (150mM NaCl, 10mM HEPES pH 7, 6mM MgCl2, 2mM DTT, 10% glycerol, 1X 424	
protease inhibitors, 200uM sodium orthovanadate) on ice for 10 minutes. Lysates were subjected to 425	
three 10-second cycles of sonication (Branson Sonifier 250), output ~2, and clarified at 1000 x g for 426	
10 minutes at 4°C. 40ml protein G agarose beads (Pierce) per sample were incubated with 2µg FLAG 427	
antibody (Sigma, F7425) for 1.5h on a rotator at 4°C before being added to the cell lysates and 428	
incubated a further 3-4 hours. Beads were harvested and washed 4 times in RIPA buffer, and cross-429	
links were reversed in 25µl reverse cross-link buffer (10mM EDTA, 5mM DTT, 1% SDS) at 65°C 430	
for 45 minutes. Proteins were eluted from beads by adding 3µl of 2X Laemmli SDS buffer and boiling 431	
at 95oC for 10 minutes. For GFP-trap experiments, 293T cells were transfected with 800ng of Rep- 432	
and/or NIPP1-expressing constructs. 24h after transfection, cells were harvested as described above, 433	
and cell lysates were incubated with 30µl NHS-activated sepharose (GEhealthcare) covalently linked 434	
to GFP nanobodies. Beads were harvested as described above.  435	
 436	
Infections 437	
 For KAP1 depletion, 293T cells were transduced with a lentiviral vector expressing either a hairpin 438	
targeting the 3’UTR of KAP1, or the corresponding empty vector, 48h before infection with 439	
AAV2/Ad5. Cells were infected at ~80% confluency with 10 IU/cell of AAV2 unless stated 440	
otherwise in ~2/5 the normal well volume. 2h after AAV2 infection, Ad5 was added at an MOI of 2 441	
PFU/cell, and medium was replaced with fresh DMEM + 10% FBS 1h after Ad5 infection. Cells 442	
were harvested for qPCR, RT-qPCR, or western blot ~42h after infection, or when they displayed 443	
optimal cytopathic effect (CPE). Optimal CPE is defined by cells that display a rounded and enlarged 444	
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phenotype, as opposed to the normal “star-shaped” morphology of HEK293T cells, and which are 445	
beginning to detach but still appear bright and healthy. Cells that had completely lifted by the time 446	
of harvest were deemed too advanced in the infection cycle and were excluded from analysis.  447	
 448	
ChIP-qPCR 449	
 Cells were cross-linked in their medium in 1% formaldehyde (10’ at room temperature) and 450	
quenched with 0.125M glycine (5’ at room temperature) before being lysed in 1mL/1x108 cells lysis 451	
buffer (50mM Tris-HCl, pH 8, 10mM EDTA, 1% SDS, 1x protease inhibitors) for 10’ on ice. Lysates 452	
were sonicated to obtain 200- to 500-bp fragments (15 x 30” cycles with 90” intervals, output ~2). 453	
10ml of lysates were used to assess sonication efficiency by reverse cross-linking for 15’ at 95°C and 454	
then incubating with RNAse A for 30’ at 37 degrees. DNA was extracted and visualized on a 1.5% 455	
agarose gel. The remaining lysates were clarified at 13,000 rpm for 10’ at 4 degrees. The equivalent 456	
of 2x106 cells was diluted 25-fold in RIPA buffer (50mM Tris pH8, 150mM NaCl, 2mM EDTA, pH 457	
8, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1x protease inhibitors) and pre-cleared with 458	
80ml protein G agarose beads (pre-blocked in 0.1mg/mL BSA for 30’) for 2h on a rotator at 4°C. For 459	
the immunoprecipitation, antibodies were added to lysates and incubated with antibody for 1h on a 460	
rotator at 4°C (5mg IgG [Abcam; ab37415], 4mg H3K9me3 [Abcam; ab8893], 1mg KAP1 [Abcam; 461	
ab10483]), before adding 80ml pre-blocked beads and incubating overnight as above. Beads were 462	
harvested and washed 4 times in RIPA buffer, 4 times in high salt wash (20mM Tris-HCl, pH 8, 463	
1mM EDTA, 500mM NaCl, 0.5% NP-40, 1x protease inhibitors), 4 times in TE buffer (10mM Tris-464	
HCl, pH8, 1mM EDTA), and eluted in 160ml elution buffer (100mM HaHCO3, 1% SDS) for 15’ at 465	
30°C. Cross-links were reversed by adding NaCl to a final concentration of 0.2M and incubating 466	
overnight at 67°C. Eluates were then incubated with 2ml RNase A (10mg/mL) and 2ml proteinase K 467	
(20mg/mL) at 45 degrees for 1h. DNA was extracted using a PCR purification kit (Qiagen) and 468	
analyzed by qPCR using primers specific for GAPDH, ZNF180, ZNF274, or various regions of the 469	
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AAV2 genome.  Purified chromatin was diluted 10-fold and quantified by real-time PCR using the 470	
SYBR Green JumpStart Taq ReadyMix for QPCR (Sigma-Aldrich) using an ABI PRISM system 471	
(Applied Biosystems). Primer sequences are listed in the Extended Data Table 2. CT values for “10% 472	
input” were adjusted by subtracting 3.322 cycles to correct for the 10-fold dilution factor 473	
(https://www.thermofisher.com/uk/en/home/life-science/epigenetics-noncoding-rna-474	
research/chromatin-remodeling/chromatin-immunoprecipitation-chip/chip-analysis.html). Percent 475	
input was then calculated as follows: 100 x 2^-(CT of adjusted 10% input - CT of ChIP-ed DNA). 476	
Percent input for each antibody was then normalized to values for IgG to calculate final fold 477	
enrichment.  478	
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Figure Legends 648	
Fig. 1. The latent AAV2 genome is repressed through KAP1 recruitment to the rep ORF and 649	
subsequent histone methylation. (A-C), AAV2 replication in control (shEMPTY) or KAP1-depleted 650	
(shKAP1) 293T cells. (A), Viral genome replication. (B), Rep and cap transcripts. Transcript levels 651	
represent fold changes over control cells infected with AAV2 + Ad5. Data are reported as 652	
mean±SEM, n=5. (C), AAV2 replication in KAP1-depleted cells complemented with exogenous 653	
KAP1. Data are reported as mean±SEM, n=4. (D), ChIP-qPCR performed on control or KAP1-654	
depleted 293T cells infected with AAV2 (100 IU/cell) using anti-KAP1 antibody or IgG. Purified 655	
chromatin was analyzed by qPCR using primers for the viral p5 promoter or various regions of the 656	
rep and cap ORFs (right panel). GAPDH was used as a negative control, and the zinc finger genes 657	
ZNF180 and ZNF274 were used as positive controls (left panel). (E), ChIP-qPCR performed as 658	
described above, using anti-H3K9me3 antibody. Values represent fold enrichment over IgG. Values 659	
are reported as mean±SEM for 3 independent experiments. (F-H), AAV2 replication and protein 660	
expression in 293T cells depleted for CHD3 (siCHD3) and/or SETDB1 (siSETDB1). (F), AAV2 661	
capsid (VP) protein expression and depletion of CHD3 and SETDB1 analyzed by western blotting. 662	
(G), Quantification of VP3 levels using ImageJ software. (H), Viral genome replication analyzed by 663	
real time qPCR. Values are reported as mean±SEM, n=4. Statistical significance was determined by 664	
unpaired t test, *P < 0.05. 665	
  666	
  Fig. 2. Phosphorylation of KAP1-S824 is necessary for AAV2 transcription and replication. (A), p-667	
KAP1-S824 in 293T cells infected with 10-10,000 gcp/cell of either AAV2 or rAAV2 in the presence 668	
of Ad5. (B), ChIP-qPCR performed as described for Fig. 1 D, E in 293T cells infected with AAV2 669	
	 28	
(100 IU/cell), with or without Ad5, n=1. (C-D), AAV2 genome replication in 293T cells 670	
overexpressing KAP1WT, (C), or KAP1S824D, (D). Values are reported as mean±SEM, n=4. (E-F), 671	
AAV2 replication in control cells and KAP1-depleted cells reconstituted with KAP1WT, KAP1S824D, 672	
KAP1S824A, or treated with an empty vector control (EV). (E), Viral genome replication. Values are 673	
reported as mean±SEM, n=4. (F), AAV2 capsid (VP) and KAP1 protein levels. (G), AAV2 674	
transcription in control cells and KAP1-depleted cells complemented with KAP1WT, KAP1S824D, or 675	
KAP1S824A, or treated with an empty vector control (EV) 16h after infection with AAV2 (1 IU/cell) 676	
alone. Values are reported as mean±SEM, n=4. Statistical significance was determined by unpaired 677	
t test, *P < 0.05, **P < 0.01, ***P < .001. 678	
     679	
Fig. 3. Rep52 and Rep78 mediate phosphorylation of KAP1-S824 through interactions with the 680	
protein phosphatase PP1.  (A), p-KAP1-S824 in 293T cells infected with Ad5 alone, or coinfected 681	
with Ad5 and either AAV2 or rAAV2 (1,000 gcp/cell) monitored at 4, 18, 24, and 42 h post infection. 682	
(B), p-KAP1-S824 in 293T cells expressing the indicated Rep proteins. Values are reported as 683	
mean±SEM n=3.  (C), GFP trap performed in 293T cells expressing Rep52 and GFP-tagged PP1, 684	
PP1, PP1, or a GFP control. (D-F), AAV2 replication and transcription at different time points 685	
in 293T cells depleted for PP1 (siPP1), PP1 (siPP1), or both (siPP1/siPP1). (D), PP1 686	
depletion analyzed by western blotting. (E), AAV2 genome replication. Values are reported as 687	
mean±SEM, n=7. (F), transcription from the three AAV2 promoters. Values are reported as 688	
mean±SEM, n=4. (G), Co-IP of FLAG-tagged proteins from 293T cells expressing FLAG-PP1 or 689	
a FLAG-GFP control and the indicated Rep proteins. (H), Immunoblot of p-KAP1-S824 in 293T 690	
cells transfected with either Rep52, or Rep52K372A. Protein levels were quantified using ImageJ 691	
software. Values are reported as mean±SEM n=3.  Statistical significance was determined by 692	
unpaired t test, *P < 0.05, **P < 0.01, ***P < .001. 693	
              694	
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Fig. 4. Rep proteins interfere with NIPP1-PP1 complex to antagonize KAP1-S824 695	
dephosphorylation. (A), Schematic representation of NIPP1 mutants. The N-terminal FHA domain is 696	
shown in blue, and FHAm denotes the FHA binding mutant, which is unable to recruit 697	
hyperphosphorylated proteins. The central PP1 binding domain containing the consensus PP1 698	
binding site RVTF is shown in yellow. RATA denotes the PP1 binding mutant. The C-terminal PP1 699	
interaction and inhibitory domain is shown in green, and the RNA binding region is shown in lime. 700	
(B), Cross-linked GFP trap performed in cells expressing Rep52 and each of the GFP-tagged NIPP1 701	
constructs, or a GFP control. (C), Immunoblot of p-KAP1-S824 in cells expressing NIPP1-WT, -702	
RATA, -FHAm or empty vector (EV) control. (D), Quantification of p-KAP1-S824 levels in C. 703	
Values are reported as mean±SEM, n=4. (E), Immunoblot of p-KAP1-S824 in cells expressing Rep52 704	
and NIPP1-WT, -RATA, -FHAm or an empty vector (EV) control (F), Quantification of p-KAP1-705	
S824 levels in e. Values are reported as mean±SEM, n=5. (G), Cross-linked GFP trap performed in 706	
cells expressing NIPP1-WT-GFP and T7-tagged Rep52, Rep52K372A or a Renilla control. Statistical 707	
significance was determined by unpaired t test, *P < 0.05. 708	
 709	
Fig. 5. Model for release of AAV2 from KAP1-mediated latency. (A) Incoming AAV2 genomes 710	
undergo second-strand synthesis, concatamerization, and chromatinization upon nuclear entry. KAP1 711	
is recruited to the rep ORF via an unknown binding partner where it forms a scaffold for the 712	
recruitment of SETDB1 and CHD3, leading to the methylation of AAV2-associated histones. NIPP1 713	
is recruited to KAP1 via the FHA domain, where it serves to tether inactive PP1 to KAP1. (B), Upon 714	
coinfection, KAP1 repression is partially lifted through several potential mechanisms – (1) helper-715	
mediated degradation of KAP1 as we have observed, (2) interference with KAP1 SUMOylation as 716	
observed by others(51), and/or (3) phosphorylation of KAP1-S824 triggered by initial helper- or 717	
AAV-mediated stress response – allowing for , (C), upregulation of rep by Ad5 E1A. Unknown 718	
cellular factors/RNA binding inactivates NIPP1 allowing PP1 to restore baseline levels of p-KAP1-719	
	 30	
S824. (D), Sequestration of PP1 by Rep sustains enhanced levels of phosphorylated KAP1-S824 to 720	
support lytic replication. 721	
 722	
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Plasmids 3	
pcDNA-mycBirAR118G, pCMV-Rep40 (pND229), pCMV-Rep52 (pND230), pCMV-Rep68 4	
Y156F M225G (pND226), and pCMV-Rep78 Y156F M225G (pND227) have been previously 5	
described (45). BirA* and each of the Rep sequences were amplified by PCR, after which 6	
overlapping PCR was used to fuse the BirA* fragment to the N-terminus of each Rep fragment. The 7	
resulting amplicons were cloned into pcDNA3.1+. FLAG- and T7-tagged Rep proteins were 8	
generated by cloning of Rep PCR products into either the pEGFP-C1 vector (Clontech) containing 9	
N-terminal FLAG tag or T7 tag, respectively. K372A mutants were generated by site-directed 10	
mutagenesis. ZNF truncation mutants were generated by PCR amplification of aa 1-529 (Δ91/87), 1-11	
558 (Δ63), or 1-577 (Δ44), using either pND230 or pND227 as a template. The amplified fragments 12	
were then cloned into the N-terminal T7 vector described above. FLAG-PP1α was generated by 13	
cloning of PCR-amplified PP1α from an EST clone obtained from Genome Cube (Clone 14	
IRAUp969F0817D) into the N-terminal FLAG-vector described above. pC1-FLAG-wtKAP1 was 15	
provided by Helen Rowe and was used for cloning of PCR-amplified wtKAP1 into untagged 16	
pcDNA3.1+. PP1γ-NIPP1, and NIPP1-WT, -RATA, -FHAm, -aa1-142, -aa143-224, -aa225-251, -17	
aa1-224, and -aa143-351 fused to eGFP were provided by Mathieu Bollen.  18	
 19	
Western Blot Analysis 20	
 Cells were lysed in RIPA buffer, and proteins were separated on a 6-12% SDS-PAGE gel and 21	
transferred to a nitrocellulose membrane (Hybond-C Extra nitrocellulose, Amersham Biosciences). 22	
Membranes were blocked with either 5% nonfat dry milk or 2.5% BSA (for phospho-antibodies) in 23	
PBS containing 0.5% Tween-20 (PBST) for 45 minutes at RT and then incubated with primary 24	
antibody for 2h at room temperature. The membranes were then washed 3x10’ in PBST and incubated 25	
	 2	
with HRP-conjugated anti-mouse or anti-rabbit IgG (BioRad) for 1h at RT. After 3x10’ washes in 26	
PBST, membranes were developed using West Pico ECL reagent (Thermo Scientific). The following 27	
primary antibodies were used: HSP90 (Santa Cruz, sc-69703; 1:10,000), KAP1 (Chemicon, 28	
MAB3662; 1:000), p-KAP1-S824 (Bethyl, A300-767A; 1:2000), VP (ARP, 03-61058; 1:500), Rep 29	
(Progen, 61069; 1:100), dsRed (Clontech, 632496; 1:2000), CHD3 (Bethyl, A301-219A; 1:4000), 30	
SETDB1 (Abcam, ab12317; 1:1000), FLAG (Sigma, F1804; 1:1000), T7 (Merck Millipore, 69522-31	
3; 1:10,000), pChk2 (NEB, 2661S; 1:1000), GFP (Roche, 11814460001; 1:5000), PP1α (Cambridge 32	
Bioscience, A300-904A; 1:1000), PP1β (Cambridge Bioscience, A300-905A; 1:1000), PP1γ (Santa 33	
Cruz, sc-6108; 1:1000),  and avidin peroxidase (Sigma; 1:8000). 34	
 35	
Lentiviral transductions 36	
 pC-SIREN-based lentiviral vectors expressing either a hairpin targeting the 3’UTR of KAP1 37	
(shKAP1; GATCCGCCTGGCTCTGTTCTCTGTCCTTTCAAGAGAAGGA CAGAGAACAGAG 38	
CCAGGTTTTTTACGCGTG) or the corresponding empty vector (shEMPTY) were provided by 39	
Helen Rowe. pCSIG-eGFP lentiviral vectors provided by Stuart Neil were modified to contain the 40	
truncated CMVΔ5 promoter (60) in place of the SFFV promoter, and to express KAP1-WT, KAP1-41	
S824D, or KAP1-S824A. Lentiviral vector-containing supernatants were produced by the common 42	
triple transfection method using the VSV-G plasmid, HIV-Gag/Pol/Rev/Tat packaging plasmid, and 43	
the lentiviral transfer plasmid in a 3:2:1 molar ratio. Supernatants were harvested 48 and 72 hours 44	
after transfection, pooled, filtered, and frozen at -80oC until use. For transduction, 1 x 106 293T cells 45	
were transduced in a 6-well format using 0.5-1.6 mL of particle-containing supernatant diluted with 46	
the appropriate amount of DMEM + 10% FBS. For complementation experiments, cells were 47	
transduced with pCSIG-based expression constructs and either shKAP1 or shEMPTY 72h later. Cells 48	
were then infected with AAV and Ad5 48h after knockdown.  49	
 50	
	 3	
Immunofluorescence 51	
293T cells were seeded at a density of 2x105/mL on poly-L-lysine (Sigma) coated coverslips in 24-52	
well plates the day prior to transfection. 4h prior to transfection, DMSO or ATMi was added to the 53	
appropriate wells to a final concentration of 10µM. Cells were then transfected with 20ng of empty 54	
vector or pRep78-GFP using 2µl Lipofectamine 2000 in 50µl serum-free Opti-mem. The next day, 55	
cells were infected with Ad5 (2 PFU/cell) in a total volume of 160µl for 1 h, after which the medium 56	
was replaced with fresh DMEM + 10% FBS. Cells were fixed 24h after Ad5 infection in 4% PFA 57	
for 10’ at room temperature, washed in PBS, permeabilized in 0.1% Triton-X-100 for 10’ at room 58	
temperature, and washed again in PBS. Cells were then incubated with primary antibody (α-p-KAP1-59	
S824 antibody; 1:1000) diluted in PBS + 1% BSA for 2h at room temperature, washed, and then 60	
incubated with secondary antibody (Biolegend; rabbit IgG2b-AlexaFluor 594, 1 µg/ml (1:1000) 61	
diluted in PBS for 1h at room temperature. Cells were then washed a final time and mounted in 62	
Prolong Gold Antifade Reagent (Invitrogen). Images were visualized using an Eclipse Ti-E Inverted 63	
confocal microscope and analyzed with NIS Elements C software. 64	
 65	
siRNA transfections. In a 24-well format, 2 x 105 cells were transfected with 50nM (siKAP1.2 66	
[GAAAUGUGAGCGUGUACUG] and siKAP1.4 [GAACGAGGCCUUCG GUGAC]) or 100nM 67	
(siCHD3 [Dharmacon, L-005046-00-0005] and siSETDB1 [Dharmacon, L-020070-00-0005]) 68	
siRNA using 2ul Dharmafect (Dharmacon) in 50ul Optim-mem (Gibco). 6h later, medium was 69	
replaced with fresh DMEM + 10% FBS. 24h after transfection, cells were re-plated into 12-well 70	
format. 36h after transfection, cells were subjected to a second transfection as described above, using 71	
4ul Dharmafect in 100ul Opti-mem. 4h after the second transfection, cells were infected with 10 72	
IU/cell AAV2 and 2 PFU/cell of Ad5 as described for the viral replication experiments. For PP1 73	
depletion experiments, cells were transfected only once with a total of 40nM siPP1α (Dharmacon, L-74	
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008927-00-0005), siPP1β (Dharmacon, L-008685-00-0005), or both as described above. 24h after 75	
transfection, cells were re-plated into a 12-well format for infection the next day as described above. 76	
 77	
Real-time PCR 78	
For analysis of viral replication, total DNA was extracted using the Qiagen DNeasy Blood and Tissue 79	
DNA extraction kit.  Viral DNA was quantified by real-time PCR using the SYBR Green JumpStart 80	
Taq ReadyMix for qPCR (Sigma-Aldrich) using an ABI PRISM system (Applied Biosystems). Cap 81	
and Ad5 100kd-specific primers and a pDG-based (61) standard curve were used for absolute 82	
quantification; the signal was normalised to cyclophilin. Primers: Cap FW (5’ – 83	
TTCTCAGATGCTGC GTACCGGAAA – 3’), Cap RV (5’ – 84	
TCTGCCATTGAGGTGGTACTTGGT – 3’), Ad5 100kd FW (5’- 85	
TCATTACCCAGGGCCACATT – 3’), Ad5 100kd RV (5’ – CCTCGTCCAAAACCTCCTCT – 3’), 86	
cyclophilin FW (5’ – TGCTGGACCCAAC ACAAATG – 3’), cyclophilin RV (5’ – 87	
TGCCATCCAACCACTCAGTCT – 3’). 88	
 89	
qRT-PCR 90	
 Total RNA was extracted using the RNeasy kit (Qiagen) after DNAseI (Qiagen) treatment for 15 91	
minutes at 37˚C. Reverse transcription was performed using the High Capacity Reverse Transcription 92	
kit (Applied Biosystems). cDNA was quantified by real-time qPCR on an ABI PRISM system 93	
(Applied Biosystems) using the TaqMan Universal PCR master mix (Life Technologies and custom 94	
designed primer-probe mixes (Eurofins). Primers: p5 FW (5’- AACAAGGTGGTGGATGAGT - 3’), 95	
p5 RV (5’ – CGTTTACGCTCCGTGAGATT - 3’), p40 FW (5’ – 96	
GGAAGCAAGGCTCAGAGAAA -3’) and p40 RV (5’ – CCTCTCTGGAGGTTGG TAGATA - 97	
3’). Probes: p5 (5’ - FAM-ACGTGGTTGAGGTGGAGCATGAT-TAM - 3’), and p40 (5’ - FAM-98	
AGGAAATCAGGACAA CCAATCCCGT-TAM - 3’). Relative expression levels were determined 99	
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with the ∆∆Ct quantification method using 18s ribosomal RNA (Taqman Pre-developed assay 100	
reagents, human 18S rRNA, Applied Biosystems) as a housekeeping reference gene. 101	
 102	
Analysis of p-KAP1-S824 levels 103	
 Phosphorylation of KAP1-S824 was investigated in 293T cells that were either infected with 104	
AAV2/Ad5 or transfected with various Rep-expressing constructs using linear PEI or NIPP1-105	
expressing constructs using TransIT-LT1 (Mirus). Where relevant, cells were pretreated with either 106	
DMSO or 10µM ATMi 4h prior to infection/transfection, and inhibitors were maintained throughout. 107	
Infections were performed as described above, and transfections were performed at ~70% confluency 108	
using 1µg DNA/8x105 cells and 4µl PEI/µg DNA. Medium was changed 6h after transfection, and 109	
cells were harvested for western blot 27h after infection/transfection.  110	
 111	
 112	
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 121	
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SI Figure Legends 125	
Fig. S1. The AAV2 Rep Proteins Physically Interact with KAP1. (A) Immunoblot of biotinylated 126	
proteins purified from BirA*-Rep52 BioID screen using anti-KAP1. (B), Verification of BioID using 127	
exogenous FLAG-KAP1; purified biotinylated proteins from 293T cells expressing FLAG-KAP1 128	
with either empty vector (EV) or BirA*-Rep52 were analyzed for Rep and KAP1 by western blot. 129	
(C), Cross-linked co-IP for FLAG-tagged proteins from 293T cells expressing FLAG-KAP1 or a 130	
FLAG-GFP control and each of the four Rep proteins. (D), Cross-linked co-IP for FLAG-tagged 131	
proteins from lysates of 293T cells expressing FLAG-GFP, FLAG-Rep40, FLAG-Rep52, FLAG-132	
Rep68, or FLAG-Rep78 and KAP1 from transfected 293T cells.     133	
 134	
 Fig.  S2. AAV2 replication and protein expression in KAP1-depleted cells. (A) Rep and capsid 135	
protein (VP) expression, and KAP1 knockdown efficiency in AAV2 and Ad5 infected control 136	
(shEMPTY) and KAP1-depleted (shKAP1) 293T cells. Data are reported as mean±SEM, n=3. (B), 137	
AAV2 replication in control (siCTRL) or KAP1-depleted (siKAP1.2/siKAP1.4) cells. Viral genome 138	
replication was analyzed by qPCR, and KAP1 knockdown efficiency was analyzed by western blot. 139	
Data are reported as mean±SEM, n=4. (C), AAV2 capsid (VP) and KAP1 protein levels at different 140	
time points in control cells and KAP1-depleted cells complemented with shRNA-resistant KAP1 or 141	
an empty vector control (EV) and coinfected with AAV2 and Ad5.  142	
 143	
Fig. S3. ChIP-qPCR performed on control or KAP1-depleted 293T cells infected with AAV2 (100 144	
IU/cell). Purified chromatin was analyzed by qPCR using primers for the viral p5 promoter or various 145	
regions of the rep and cap ORFs. GAPDH was used as a negative control, and the zinc finger genes 146	
ZNF180 and ZNF274 were used as positive controls. Each of the three independent repeats are shown 147	
for (A) KAP1-specific and (B) H3K9me3-specific ChIP experiments (Fig. 1 D and E).  148	
             149	
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Fig. S4. Phosphorylation of KAP1-S824 by the Rep proteins is independent from ATM activation. 150	
(A), p-KAP1-S824 localization in 293T cells pretreated with ATMi and expressing Rep78-GFP with 151	
and without Ad5 infection (left and right panel, respectively). (B-C), p-KAP1-S824 levels analyzed 152	
in 293T cells pretreated with ATMi. (B), Cells were transfected with EV, Rep52, or Rep78. p-Chk2 153	
was monitored to assess efficiency of ATM inhibition. p-KAP-S824 levels were normalized to Rep 154	
levels to correct for differences in transfection efficiency as a result of pretreatment with ATMi. (C), 155	
Cells were infected with AAV2 and Ad5. Values are reported as mean±SEM, n=4. 156	
          157	
Fig. S5. Phosphorylation of KAP1-S824 in the presence of Rep52 and Rep78 is dependent on the 158	
Rep C-terminal zinc finger domain. (A), Schematic diagram representing full length Rep52, 159	
comprising an ATPase domain (AAA+) and zinc finger domain (ZNF), and the C-terminal truncation 160	
mutants in which the ZNF domain is progressively removed. Black bars indicated a CXXC zinc-161	
binding motif, and red bars a CXXH zinc-binding motif. (B), p-KAP1-S824 in 293T cells transfected 162	
with full length Rep52 and Rep78, or truncation mutants in which the C-terminal ZNF domain is 163	
progressively removed. Values are reported as mean±SEM, n=3. (C), Cross-linked co-IP for FLAG-164	
tagged proteins from 293T cells expressing FLAG-KAP1, or a FLAG-GFP control, with full length 165	
Rep52 or each of the Rep52 C-terminal ZNF truncation mutants. Statistical significance was 166	
determined by unpaired t test, *P < 0.05, **P < 0.01, ***P < .001. 167	
 168	
Fig. S6. Validation of Rep-K372A PP1-binding mutant. (A), Depiction of the PP1-binding site in the 169	
Rep ATPase domain. The Walker B motif is outlined in black, and the partially overlapping 170	
consensus binding site is outlined in pink. Lysine 372 alone was subjected to mutagenesis in order to 171	
preserve Rep ATPase/helicase function. (B), Rep-mediated repression of AAV2 p5 is dependent on 172	
a functional ATPase/helicase domain (62). To verify ATPase activity of Rep52K372A, 293T cells co-173	
transfected with a p5-mCherry reporter construct and Rep52 or Rep52K372A expression plasmids were 174	
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analyzed for p5 activity by western blotting for mCherry (45). Protein levels were quantified using 175	
Image J software. Values are reported as mean±SEM, n=3. (C), Cross-linked co-IP for FLAG-tagged 176	
proteins from 293T cells expressing FLAG-KAP1, or a FLAG-GFP control, with the various Rep 177	
proteins.  178	
 179	
Fig. S7. Ad5 and HSV-1 infection leads to KAP1 degradation. (A-B), Immunoblot of KAP1 in 293T 180	
cells (A) and HeLa cells (B) infected with Ad5 at the stated MOI (PFU/cell). Values are reported as 181	
mean±SEM, n=3. (C), Immunoblot of KAP1 in HeLa cells treated with MG132 at the stated 182	
concentrations and infected with 10 PFU/cell of Ad5. (D-E), Immunoblot of endogenous KAP1 in 183	
293T, (D), and HeLa, (E), cells infected with HSV-1. Values are reported as mean±SEM, n=3. 184	
Statistical significance was determined by unpaired t test, *P < 0.05, **P < 0.01, ***P < .001. 185	
 186	
Fig. S8. Model for regulation of KAP1-S824 phosphorylation by NIPP1, PP1, and Rep. Schematic 187	
representation of a model for the regulation of KAP1-S824 phosphorylation by NIPP1, PP1, and Rep. 188	
The upper series represents regulation in the absence of AAV2 infection. Inactive NIPP1-PP1 is 189	
recruited to KAP1 via the NIPP1 FHA domain. Initiation of a DNA damage response (DDR) leads 190	
to phosphorylation of KAP1-S824, allowing for heterochromatin relaxation and repair. The DDR 191	
also leads to the inactivation of NIPP1 through phosphorylation of the C-terminal region, possibly 192	
through the tyrosine kinase Lyn, allowing PP1 to restore homeostatic levels of p-KAP1-S824. In the 193	
event of AAV2/Ad5 coinfection however, Rep interferes with this pathway by competing for PP1 194	
and thus acts to maintain high levels of p-KAP1-S824 triggered by infection.  195	
 196	
                        197	
SI Table 1. Peptides identified by BioID for KAP1 and various known interaction 
partners of the Rep proteins. 
Identified  
Protein 
Accession 
Number 
Bait  
Protein 
Unique 
Peptides  
Sequence 
Coverage 
Protein ID 
Probability 
KAP1 Q13263 
BirA*-Rep40 2 3.1% 100% 
BirA*-Rep52 8 12.9% 100% 
BirA*-Rep68 3 6.0% 100% 
BirA*-Rep78 1 1.3% 100% 
RUVBL1 Q9Y265 
BirA*-Rep40 2 7.2% 100% 
BirA*-Rep52 7 22.1% 100% 
BirA*-Rep68 1 2.9% 99% 
BirA*-Rep78 1 2.9% 99% 
MRE11 P49959 
BirA*-Rep40 1 2.0% 99% 
BirA*-Rep52 8 19% 100% 
SNW1 Q5R7R9 
BirA*-Rep40 5 23.7% 100% 
BirA*-Rep52 9 24.1% 100% 
BirA*-Rep68 1 2.8% 100% 
BirA*-Rep78 2 4.3% 100% 
MDC1 Q14676 
BirA*-Rep40 2 2.0% 100% 
BirA*-Rep52 4 3.3% 100% 
BirA*-Rep68 1 0.5% 100% 
TAF1/SET Q01105 
BirA*-Rep40 1 4.8% 100% 
BirA*-Rep68 1 4.8% 100% 
NUCLEOLIN P19338 
BirA*-Rep40 1 2% 99% 
BirA*-Rep52 10 16.2% 100% 
BirA*-Rep68 13 18% 100% 
BirA*-Rep78 4 6.2% 100% 
 
      
 	
SI Table 2. ChIP-qPCR primers 
 
Gene FW RV 
GAPDH CACCGTCAAGGCTGAGAACG ATACCCAAGGGAGCCACACC 
ZNF180 TGATGCACAATAAGTCGAGCA TGCAGTCAATGTGGGAAGTC 
ZNF274 GGAGAAATCCCATGAGGGTAA GGCTTTTGTGAGAATGTTTTCC 
p5 CTGTATTAGAGGTCACGTGAGTG TCAAACCTCCCGCTTCAAA 
Rep 5’ CCGAGAAGGAATGGGAGTT CCATTCCGTCAGAAAGTCG 
Rep middle GCCTTGGACAATGCGGGAAAGATT TGTCGACACAGTCGTTGAAGGGAA 
Rep 3’ TTCCCGTGTCAGAATCTCAA CCAAATCCACATTGACCAGA 
Cap 5’ GACAGTGGTGGAAGCTCAAA TTGTACCCAGGAAGCACAAG 
Cap middle TTCTCAGATGCTGCGTACCGGAAA TCTGCCATTGAGGTGGTACTTGGT 
Cap 3’ GTCAGCGTGGAGATCGAGT AGGCTCTGAATACACGCCAT 
 	





